Skip to main
ILMN
ILMN logo

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 42 analyst ratings
Buy
Strong Buy 26%
Buy 26%
Hold 36%
Sell 10%
Strong Sell 2%

Bulls say

Illumina has demonstrated a strong ability to increase revenue historically, even while driving down the cost of sequencing, a testament to the demand elasticity in its market. With a focus on achieving high single-digit revenue growth by 2027, supported by an innovative roadmap of multiomic technologies and workflows, Illumina remains well-positioned for future expansion. Additionally, despite potential short-term challenges in international markets, the company expects a significant increase in earnings per share, projecting approximately 14% growth in 2026.

Bears say

Illumina's stock faces a negative outlook primarily due to lowered guidance for non-GAAP diluted EPS, reflecting concerns over reduced earnings contributions from the Chinese market and persistent macroeconomic trends. The company has experienced a significant decline in stock value, reportedly down about 40%, as fears surrounding its ability to operate in China and potential funding cuts from the NIH have intensified. Additionally, if Illumina fails to maintain its market share in the next-generation sequencing (NGS) market and cannot achieve revenue or earnings growth consistent with its peers, it risks trading at a continued discount relative to its competitors.

Illumina (ILMN) has been analyzed by 42 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 26% recommend Buy, 36% suggest Holding, 10% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 42 analysts, Illumina (ILMN) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $176.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $176.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.